Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) has been becoming a novel convenient and noninvasive method for dynamically monitoring landscape of genomic information to guild personalized cancer treatment. In this study we comprehensively evaluated the additional value of plasma ctDNA to routine tissue next generation sequencing (NGS) of therapeutically targetable mutations in lung cancers.

Methods

The tumor tissues and peripheral blood samples from 423 cases of patients with lung cancer were subjected to NGS of mutations in oncodrivers (EGFR, ERBB2, ALK, ROS1, C-MET, KRAS, BRAF, RET, BRCA1 and BRCA2).

Results

One hundred and ninety-seven cases showed both plasma and tissue positive and 96 showed both negative. The concordance for tissue and blood detection was 69.27% (293

SUBMITTER: Xie J 

PROVIDER: S-EPMC10063947 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature